Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
191
resultados
Última actualización
30/09/2025 [06:51:00]
Resultados 125 a 150 de 191
Resumen de: WO2025192852A1
The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition including same, the composition exhibiting excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.
Resumen de: WO2025192851A1
The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition comprising same, which exhibits excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.
Resumen de: WO2025192799A1
The present invention relates to a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL S-PAC-PEG S) micelle in which osimertinib, etoposide, and docetaxel are encapsulated, and used thereof. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein osimertinib, which is a target therapeutic agent, and etoposide and docetaxel, which are both anticancer chemotherapeutic drugs, are encapsulated in a Soluplus® polymer to form micelles, whereby anticancer activity can be effectively induced through an improvement in the solubility of the poorly soluble drug in water and a synergistic action between the drugs. The pharmaceutical composition for cancer treatment according to the present invention enables effective solubilization of osimertinib, etoposide, and docetaxel by encapsulating the poorly soluble drugs in micelles formed using the PCL-PVAc-PEG (Soluplus®) polymer, and thus can be advantageously used as an intravenous injection. With the advantage of avoiding first-pass metabolism in the liver, unlike oral dosage forms, intravenous injection can reduce unnecessary loss of drugs and also increase bioavailability compared to oral dosage forms, and thus is an effective administration method capable of expecting a high effect with the same amount of drugs. Therefore, development of such a formulation allows effective administration of osimertinib, etoposide, and docetaxel. In addition, the
Resumen de: WO2025190367A1
The present invention provides an anti-CLDN18.2 nanobody, a chimeric antigen receptor, and uses thereof, and specifically provides a single-domain nanobody and a bispecific nanobody specifically binding to CLDN18.2 or an antigen binding fragment thereof, a chimeric antigen receptor based on the nanobody specifically binding to CLDN18.2, an engineered host cell, a nanobody-drug conjugate or conjugate or composition, a pharmaceutical composition, a kit, and related methods and uses.
Resumen de: WO2025190300A1
The present application provides lipid nanoparticles comprising an ionizable lipid, a phospholipid, a structural lipid, and a PEG lipid. The lipid nanoparticles of the present application enable encapsulation and delivery of a therapeutic/prophylactic agent, safely deliver the therapeutic/prophylactic agent to a targeted position, and enable high expression, thereby exerting the effect of the therapeutic/prophylactic agent.
Resumen de: WO2025190157A1
A circular RNA vaccine for treating canine melanoma. The circular RNA vaccine contains a circular RNA molecule encoding an optimized canine tyrosinase, and the optimized canine tyrosinase comprises canine tyrosinase or a homologous sequence thereof, a linker arm, and an enhancer sequence or a homologous sequence thereof. The immunogenicity of the canine tyrosinase is enhanced by means of optimization, thereby stimulating the immune system to recognize the canine tyrosinase. In addition, the circular RNA vaccine of the canine tyrosinase is prepared by means of using a circular RNA technique and an LNP delivery technique. The optimized canine tyrosinase is highly expressed in vivo, and thus the immune system is activated to have a therapeutic effect on canine melanoma.
Resumen de: WO2025189560A1
Provided is a glaucocalyxin A nano-sized transdermal delivery system for inhibiting skin inflammation. The delivery system is a protein-glaucocalyxin A-polymer shell layer capsule composite structure. The protein has an affinity effect on the skin. Glaucocalyxin A is loaded into the protein. The surface of the protein is coated with the polymer layer. The size of the glaucocalyxin A nano-sized transdermal delivery system is 30-80 nm, and the thickness of the polymer shell layer is 10-35 nm. The surface properties of the polymer shell can be regulated according to the depth requirement of transdermal delivery, enabling the protein to break through the skin barrier and to be efficiently delivered to a deep position of the skin. Then, glaucocalyxin A is slowly released, alleviating skin inflammation in a targeted manner. The present invention overcomes the limitation of poor therapeutic efficacy caused by inadequate transdermal absorption of glaucocalyxin A in treating skin inflammation.
Resumen de: WO2025190321A1
The present invention relates to a preparation method for and an ocular use of a cellulose nanocrystal-based polymer hydrogel. Specifically provided is a method for preparing a polymer composite double-network hydrogel. The hydrogel prepared by the method of the present invention has excellent biocompatibility, good mechanical properties and high light transmittance, and the preparation process is safe and simple and has low costs.
Resumen de: WO2025189238A1
The present disclosure relates to the field of therapeutic agents and methods for the prevention, amelioration and treatment of muscle-associated diseases, disorders or conditions.
Resumen de: WO2025190968A1
The invention concerns novel apolipoprotein lipid nanoparticles.
Resumen de: WO2025190633A1
The present invention relates to a peptide of Formula (I): R2 - Arg-Pro-Pro-Gln-Gly-His-Lys - R1 (R2- SEQ ID NO: 1 -R1) (I); wherein R1 is selected from the group consisting of —OH, —OR3, —SR3, —NR3R4, —OR5 and —NHR5, R2 is selected from the group consisting of H—, R3 —C(O)— and R3—OC(O)—, R3 and R4 are independently selected from H, C1-C24 alkyl, C2-C24 alkenyl and C6-C10 aryl; R5 is selected from the group consisting of —(CH2)3- R8-CH2-NH2, - R8-R6, —(CH2)n—O- R8-R6, — CO—O- R8-R6, —CO— (CH2CH2)—CO—O- R8-R6, —CO—(CH2)m-O- R8-R6, —CO—(CH2)n—CH(R7) —O- R8-R6, —CO— (CH2)m—CH(R7)—O—CO—CH(R7)—(CH2)m-O- R8-R6 and -(1,3,5-triazine)-(O- R8-R6)2, R8 is a PEG-linker selected from the group consisting of (CH2-CH2—O)n—, (CH2-CH(CH3)—O)o—, (CH(CH3)—CH2—O)o—, (CH2-CH2—O)—(CH2—CH(CH3)—O)o—(CH2-CH2—O)p—, (CH2-CH2—O)—(CH(CH3) —CH2—O)o—(CH2-CH2—O)p—, (CH2-CH2—O)—(CH(CH3)—CH2—O)o—, (CH2-CH2—O)—(CH2-CH(CH3)—O)o—, (CH2—CH(CH3)—O)o—(CH2-CH2—O)n—, (CH(CH3)—CH2—O)o—(CH2-CH2—O)n—, (CH2—CH(CH3)—O)o—(CH2-CH2—O)n—(CH2—CH(CH3)—O)q—, (CH2—CH(CH3)—O)o—(CH2-CH2—O)n—(CH(CH3)—CH2—O)q—, (CH(CH3)—CH2O)o—(CH2-CH2—O)—(CH2—CH(CH3)—O)q— and (CH(CH3)—CH2O)o—(CH2-CH2—O)n—(CH(CH3)—CH2—O)o—, R6 is a hydrogen atom or a C1-4 alkyl group; and R7 is a C1-4 alkyl group; and n and p are integers between 1 and 10 and m an
Resumen de: US2025288534A1
The present disclosure provides a lipid nanoparticle to treat, prevent or diagnose a central nervous system disease, disorder, trauma or injury, the lipid nanoparticle comprising: a non-cationic helper lipid; a sterol; a hydrophilic polymer-lipid conjugate; an ionizable, amino amino lipid having a pKa between 5.0 and 7.0; and an mRNA having a nucleic acid sequence encoding for a secretory polypeptide for treating, preventing or diagnosing the central nervous system disease, disorder, trauma or injury, the secretory polypeptide being capable of secretion from a cell of the central nervous system into a interstitial and/or cerebrospinal fluid of a subject. Further provided are methods for administration of the lipid nanoparticles to treat, prevent or diagnose the central nervous system disease, disorder, trauma or injury and uses of such lipid nanoparticles.
Resumen de: US2025288701A1
The present invention relates to the technical field of nanotechnology and pharmaceutics, particularly, it relates to a reagent and pharmaceutical composition containing gold nanorods conjugated to D1 and Angiopep-2 peptides, and methods for detecting, diagnosing, evaluating the progression, and treating diseases related to β-amyloid plaques, such as Alzheimer's disease. Surprisingly, with the reagent and pharmaceutical composition of the present invention, a dose of gold per kg of body weight well below those previously reported is required, hence their applications are more economical, in addition to decreasing the likelihood of toxic effects, thanks to the low doses required to exert their function.
Resumen de: US2025288682A1
Provided are compositions that include colchicine conjugated to behenic acid, optionally wherein the colchicine conjugated to behenic acid is encapsulated by a nanoliposome. In some embodiments, the colchicine is conjugated to behenic acid at the acetamide position of a B-ring of colchicine, the nanoliposome includes a lipid component comprising DSPC, DOPE, and DSPE-PEG, and cholesterol; and/or the colchicine conjugated to behenic acid is present in the nanoliposome in an amount of at least about 400, 500, 600, or more than 600 pg/mL. Also provided are methods for preparing behenic acid-conjugated colchicine derivatives, methods for preparing lipid nanoparticle-encapsulated colchicine derivatives, and methods for using the same to treat and/or prevent inflammatory and/or cardiovascular diseases, disorders, and/or conditions.
Resumen de: US2025288688A1
Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.
Resumen de: US2025288604A1
Provided are compositions that include compositions of galactosyl-conjugated lipid, nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl-conjugated LNPs have a lipid component having D-Lin-MC3-DMA, ALC-0315 and SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GaIN Ac-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GaINAc-conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with undesirable gene expression and methods for targeting active agents to hepatocytes using the presently disclosed GaIN Ac-conjugated LNPs.
Resumen de: US2025288536A1
Described herein are particles including a protein and an active agent such as a particle comprising α-lactalbumin and tryptophan. Also described herein are methods of making and using particles that include a protein and an active agent.
Resumen de: US2025288524A1
Described are techniques, systems, and methods include those employing pneumatic, pressure assisted, extrusion-based 3D printing and emulsion evaporation, emulsion diffusion, nanoprecipitation, desolvation, gelation, spray-based atomization, etc. for fabricating loaded microparticles or nanoparticles that encapsulate an active pharmaceutical ingredient or live cells into a biocompatible polymer or pharmaceutical excipients. The techniques provide for encapsulation of a variety of substances including proteins, plasmid DNA, lipophilic pharmaceutical compositions, hydrophilic pharmaceutical compositions, live cells, and/or cellular components into polymeric microparticles or nanoparticles. The particles loaded with active pharmaceutical ingredients can be used for the treatment of different diseases or conditions. The particles loaded with live cells can be used for disease treatment, but can also be used for securely storing the live cells in a stable condition for transport and later use in inoculating fermentation systems, for example, to generate recombinant proteins.
Resumen de: US2025288522A1
The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
Resumen de: US2025288535A1
A nanoparticle composition for rapid suspension and a preparation method therefor. The composition comprises an active ingredient, albumin and a particle stabilizer, and optionally a lyoprotectant. The active ingredient has the following characteristics: insoluble or slightly soluble in water, and soluble or easily soluble in specific organic solvents, and is preferably paclitaxel or docetaxel.
Resumen de: US2025288605A1
Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group.
Resumen de: US2025288532A1
Nanoparticles and formulations for treating prostate cancer in a subject are disclosed. The nanoparticles contain a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying ligand is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agents can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a chemotherapy drug or a combination thereof, that kill and/or reduce or prevent growth or proliferation of gonadotroph cells and/or tumor cells, regulate FSH and/or LH secretion, and/or interfere with androgen production. Uses for formulations incorporating the nanoparticles for treating cancer in a subject are also disclosed.
Resumen de: US2025288533A1
The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from 30 mol % to 70 mol %; (iii) a ionizable, cationic lipid content of from 5 mol % to 50 mol %; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol % to 5 mol. Further provided is a lipid nanoparticle comprising encapsulated mRNA and 20 to 70 mol % of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. Further provided are methods of administration of such lipid nanoparticles.
Resumen de: US2025288531A1
A novel amino acid-based cationic lipid contains unsaturated bonds, represented by the general formula (1). The amino acids or derivatives used as starting materials in the preparation process are simple and easily obtainable, offering simplicity, safety, and cost-effectiveness. The amino acid-based cationic lipid of this invention features unsaturated hydrocarbon tails and a tertiary amine moiety derived from an amino acid residue. The lipid nanoparticles (LNPs) prepared from this lipid exhibit enhanced membrane fluidity, which improves membrane fusion and facilitates cellular uptake. As a result, the delivery efficiency of the amino acid-based cationic lipid containing unsaturated bonds as a delivery material is significantly improved.
Nº publicación: US2025289840A1 18/09/2025
Solicitante:
TEAM MEDICAL LLC [US]
Team Medical, LLC
Resumen de: US2025289840A1
The present disclosure provides compositions and methods for producing and manufacturing compositions comprising at least one or more RNA stabilizing substance and at least one or more substance comprising extracellular RNA, wherein the compositions and methods of use provided herein improve the storage and stability of substances comprising extracellular RNA or based on RNA at temperatures above freezing temperatures without lyophilization. The present disclosure, further provides compositions for improving the stability of pharmaceutical compositions comprising RNA substances or based on RNA substances, including the stability of RNA in conjunction with nanoparticles or lipid-nanoparticles and applications for improving the storage and stability of pharmaceutical compositions comprising RNA or RNA substances above freezing temperatures without lyophilization. The present disclosure also provides descriptions of kits and methods for providing or producing kits for producing compositions comprising at least one or more RNA stabilizing substance.
BOPI
Sede Electrónica
